Portfolio Optimization
Optimize your portfolio for maximum scientific and commercial impact with Thelansis.
Every company’s portfolio is different but the challenges remain same. Our consultants help biopharma teams identify where to play, which assets to prioritize, and how to allocate resources efficiently and de-risk development for long-term success.
We evaluate your pipeline through a 360° lens—epidemiology, competitive intelligence, clinical development trends, regulatory pathways, payer environments, and unmet needs—to identify the most promising indications and markets.
What We Do:
Using our proprietary data platforms and AI-backed analytics, we score each asset by disease burden, market potential, clinical success probability, payer dynamics, and strategic fit.
We model multiple development scenarios to highlight: capital-efficient routes to market, high-risk vs. high-reward opportunities, early termination candidates, co-development or out-licensing options, portfolio risk distribution.
In the current scenario, the competitive landscape of oncology TA, where innovation moves rapidly, pharma companies face intense pressure to optimize their pipeline investments. With hundreds of potential cancers and limited resources, selecting the most promising therapeutic indications for early-stage assets is both critical and complex. Traditional prioritization methods usually rely on manual literature reviews, expert panels, and historical analogs, lagging to keep pace with the dynamic nature of clinical, regulatory, and market data, which in turn delays portfolio actions.
Learn more: Smart Pipeline Decisions: AI-Powered Indication Prioritization for Oncology TA
A US-based mid-size biotech firm was preparing for its upcoming investment cycle to broaden its therapeutic area focus. The team had strong scientific instincts but lacked a unified, evidence-based approach to compare opportunities across disease areas, evaluate commercial risk, and pressure-test assumptions in volatile market conditions. Their existing datasets were scattered, inconsistent, and not structured to support quick, high-stakes investment calls.
Learn more: Optimizing Biotech Investment Strategy in an Uncertain Market Landscape
We Provide Answers to Critical Questions:
Each recommendation is backed by rigorous data, market intelligence, and scientific reasoning. Through deep scenario planning and future-outlook modelling, we identify untapped therapeutic areas, white-space opportunities, and competitive blind spots, helping you expand intelligently and sustainably.
Which indications should we pursue first?
Where should we invest, partner, or diversify?
Which assets need repositioning or de-prioritization?
What is the most efficient path to value creation?
Need customize support?
Thelansis also caters to your specific needs by providing customized reports that satisfy your organizational requirements. Get on-demand customization of the report’s scope to exactly meet your needs.